{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "Patient with locally advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). Patient has never smoked or has a history of light smoking and has adenocarcinomas. Patient with metastatic lung adenocarcinoma staging as cT3N2M0 IIIB.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0006826",
              "label": "Lung Cancer",
              "status": "active"
            },
            {
              "code": "C4021843",
              "label": "anaplastic lymphoma kinase positive non-small cell lung cancer",
              "status": "active"
            },
            {
              "code": "C0001654",
              "label": "Adenocarcinoma",
              "status": "active"
            }
          ],
          "social_history": [
            {
              "category": "smoking",
              "status": "never",
              "description": "Patient has never smoked or has a history of light smoking"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Patient received neoadjuvant alectinib at a dosage of 600 mg twice per day for 56 days (two cycles), resulting in a partial response with a tumor shrinkage of 47%.",
        "clinical_data": {
          "medications": [
            {
              "drug": "alectinib",
              "dosage": "600 mg",
              "frequency": "twice per day",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "Neoadjuvant"
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "partial response",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Patient underwent lobectomy and systemic lymphadenectomy, achieving major pathological response (MPR) with 7% remaining tumor cells.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Lobectomy",
              "approach": "open",
              "outcome": "Major pathological response",
              "location": "lung"
            },
            {
              "name": "Lymphadenectomy",
              "approach": "open",
              "outcome": "Major pathological response",
              "location": "lymph nodes"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "51-year-old non-smoking man presented for a routine physical examination due to right foot numbness. Patient has a history of hypertension managed with oral medications.",
        "clinical_data": {
          "social_history": [
            {
              "category": "smoking",
              "status": "never"
            }
          ],
          "diagnoses": [
            {
              "code": "http://purl.bioontology.org/ontology/SNOMEDCT/59620008",
              "label": "Hypertension",
              "status": "active"
            }
          ],
          "HPI": [
            {
              "summary": "right foot numbness",
              "onset": "unknown"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Chest X-ray showed a high-density nodule located in the right upper lobe. Enhanced chest CT revealed a 31 mm nodule with enlarged mediastinal lymph nodes at 4R and 10R. Transbronchial needle aspiration was performed at stations 4R and 10R through endobronchial ultrasound. Enhanced brain MRI and PET-CT showed no distant metastasis. Pathologic evaluation showed metastatic lung adenocarcinoma and the clinical stage was IIIA (cT2N2M0).",
        "clinical_data": {
          "imaging": [
            {
              "type": "Radiography, Thoracic (TUI)",
              "body_part": "Lung (TUI)",
              "modality": "X-ray",
              "finding": "high-density nodule",
              "date": null
            },
            {
              "type": "Computed tomography of chest (TUI)",
              "body_part": "Mediastinum (TUI)",
              "modality": "CT",
              "finding": "enlarged mediastinal lymph nodes at 4R and 10R",
              "date": null
            },
            {
              "type": "Magnetic resonance imaging of brain (TUI)",
              "body_part": "Brain (TUI)",
              "modality": "MRI",
              "finding": "no distant metastasis",
              "date": null
            },
            {
              "type": "Positron emission tomography (TUI)",
              "body_part": "Lung (TUI)",
              "modality": "PET",
              "finding": "no distant metastasis",
              "date": null
            }
          ],
          "procedures": [
            {
              "name": "Transbronchial Needle Aspiration (TUI)",
              "approach": "endoscopic",
              "date": null,
              "location": "stations 4R and 10R",
              "performed_by": null,
              "outcome": null
            }
          ],
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Lung Adenocarcinoma",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Immunohistochemistry (IHC) revealed positive staining of cytokeratin AE1/AE3, thyroid transcription factor-1 (TTF-1), and Napsin A. ALK fusion status was positive by IHC (D5F3) and FISH (Vysis ALK Break Apart FISH Probe Kit; Abbott, IL, USA). The percent of rearranged cells in FISH was 45.7%. Multi-disciplinary team consultation by the department of respiratory, thoracic surgery, radiotherapy (RT), pathology and radiology.",
        "clinical_data": {
          "imaging": [
            {
              "modality": "other",
              "type": "Immunohistochemistry",
              "finding": "positive staining of cytokeratin AE1/AE3, thyroid transcription factor-1 (TTF-1), and Napsin A"
            },
            {
              "modality": "other",
              "type": "Immunohistochemistry",
              "finding": "ALK fusion status was positive by IHC (D5F3)"
            },
            {
              "modality": "other",
              "type": "FISH",
              "finding": "ALK fusion status was positive by FISH (Vysis ALK Break Apart FISH Probe Kit; Abbott, IL, USA). The percent of rearranged cells in FISH was 45.7%"
            }
          ],
          "procedures": [
            {
              "name": "Multi-disciplinary team consultation",
              "location": "department of respiratory, thoracic surgery, radiotherapy (RT), pathology and radiology"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Patient started on neoadjuvant alectinib at a dosage of 600 mg twice per day from April 28, 2020.",
        "clinical_data": {
          "medications": [
            {
              "drug": "alectinib",
              "dosage": "600 mg",
              "frequency": "twice per day",
              "modality": "oral",
              "start_date": "2020-04-28",
              "end_date": null,
              "indication": "neoadjuvant"
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "After one cycle (28 days) of neoadjuvant alectinib therapy, CT and PET-CT scan confirmed a 42.2% tumor shrinkage. Clinical stage was IIIA (cT1N2M0). Patient was evaluated as partial remission (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patient did not show any side effects with alectinib treatment.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Computed tomography",
              "body_part": "tumor",
              "modality": "CT",
              "finding": "42.2% tumor shrinkage",
              "date": null
            },
            {
              "type": "Positron emission tomography",
              "body_part": "tumor",
              "modality": "PET",
              "finding": "42.2% tumor shrinkage",
              "date": null
            }
          ],
          "diagnoses": [
            {
              "code": "cT1N2M0",
              "label": "Clinical stage IIIA",
              "status": "active",
              "onset_date": null
            }
          ],
          "medications": [
            {
              "drug": "alectinib",
              "dosage": null,
              "frequency": null,
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "Neoadjuvant therapy"
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Patient underwent right upper lobectomy with mediastinal lymph node dissection by VATS after 45 days (2020/4/28\u20132020/6/11) of alectinib treatment. Mediastinal lymph node station 4R was inoperative due to severe tissue adhesion. Patient discharged 5 days post-operation without complications. Pathologic evaluation with hematoxylin and eosin staining and IHC showed residual viable tumor cells at 15%, indicating MPR was not achieved.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Lobectomy",
              "approach": "VATS",
              "date": null,
              "location": "right upper lobe",
              "performed_by": null,
              "outcome": null
            },
            {
              "name": "Lymph Node Dissection",
              "approach": "VATS",
              "date": null,
              "location": "mediastinal lymph node",
              "performed_by": null,
              "outcome": null
            }
          ],
          "medications": [
            {
              "drug": "alectinib",
              "dosage": null,
              "frequency": null,
              "modality": "oral",
              "start_date": "2020-04-28",
              "end_date": "2020-06-11",
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "severe tissue adhesion",
              "status": "active",
              "onset_date": null
            }
          ],
          "labs": [
            {
              "test": "hematoxylin and eosin staining",
              "value": null,
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "IHC",
              "value": null,
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "Patient received adjuvant alectinib (600 mg oral BID) a week after surgery. Multi-disciplinary team consultation recommended sequential radiotherapy (RT) combined with alectinib therapy due to the patients without systematic mediastinal lymph node dissection (station 4R excluded",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1608377",
              "dosage": "600 mg",
              "frequency": "BID",
              "modality": "oral",
              "start_date": null,
              "end_date": null
            }
          ],
          "procedures": [
            {
              "name": "C0036323",
              "date": null,
              "location": "mediastinal lymph node"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initiation of neoadjuvant alectinib therapy.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1608377"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Surgical intervention following neoadjuvant alectinib, resulting in lobectomy and lymphadenectomy.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C0162754",
            "C0024253"
          ],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Interval period. New presentation of right foot numbness and history of hypertension.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0236344"
          ],
          "change_type": "addition",
          "target_domain": "symptom"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Imaging and diagnostic procedures revealing lung nodule and mediastinal lymph node enlargement, leading to diagnosis of metastatic lung adenocarcinoma.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Detailed pathological evaluation and multidisciplinary team consultation.",
        "transition_event": {
          "trigger_type": "interpretation",
          "trigger_entities": [],
          "change_type": "other",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Initiation of neoadjuvant alectinib therapy.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1608377"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2020-04-28T00:00:00Z"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Response evaluation after one cycle of alectinib, showing tumor shrinkage and partial remission.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Surgical intervention with lobectomy and lymph node dissection following alectinib treatment.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C0162754",
            "C0024253"
          ],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true,
        "content": "Adjuvant alectinib therapy and recommendation for sequential radiotherapy.",
        "transition_event": {}
      }
    }
  ]
}